Prognostic value of CD34 expression status in patients with myxofibrosarcomas and undifferentiated pleomorphic sarcomas

Figures

• 

  Figure 1. Histology and CD34-immunostaining of myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS). (a and b) MFS: Pleomorphic sarcoma with myxoid stroma (hematoxylin and eosin stain; original magnification, ×40 in A and ×400 in B. (c) MFS: The cytoplasm and cell membrane are strongly positive for CD34 (immunostaining, original magnification, ×400). (d and e) UPS: Pleomorphic sarcoma with non-myxoid stroma (hematoxylin and eosin stain; original magnification, ×40 in d and ×400 in e). (f) UPS: The cytoplasm and cell membrane are strongly positive for CD34 (immunostaining, original magnification, ×400).

• 

  Figure 2. Survival curves of patients with myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS). When MFS was defined as a myxoid component of > 50%, there was no significant difference in overall survival between patients with MFS and those with UPS (a). On the other hand, patients with MFS showed significantly better overall survival than did those with UPS when MFS was defined as having a myxoid component > 10% (b). Local recurrence-free survival didn’t show significant differences between patients with the two types of diseases under the both definition of MFS (c: myxoid component of > 50%; d: > 10%). Distant metastasis-free survival also didn’t show significant differences between patients with the two types of diseases under the both definition of MFS (e: myxoid component of > 50%; f: > 10%).

• 

  Figure 3. Survival curves of CD34-positive and CD34-negative patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Among all patients, those who were CD34-positive showed significantly better overall and distant metastasis-free survival (a and b), but not local recurrence-free survival (c), than those who were CD34-negative.

• 

  Figure 4. Overall survival of patients with myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) according to CD34 status. Patients who were CD34-positive showed significantly better overall survival than did those who were CD34-negative whether they were diagnosed with MFS (a) or UPS (b).